Podcast Episode
View More
Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer, including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides, commentaries, podcast, on-demand Webcast, and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors.
Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer
In an engaging discussion led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Dr. Sara Hurvitz, MD, FACP, share how they currently use CDK4/6 inhibitors for their patients with metastatic HR-positive/HER2-negative breast cancer, the potential clinical implications of key studies on CDK4/6 inhibitors from ASCO 2021, and strategies for counseling patients receiving CDK4/6 inhibitors.
Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer
Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Released: August 19, 2021
Downloadable slides accompanying a podcast led by Joyce O’Shaughnessy, MD, Matthew P. Goetz, MD, and Sara Hurvitz, MD, FACP, about how they use CDK4/6 inhibitors for patients with HR-positive/HER2-negative breast cancer, including key studies on CDK4/6 inhibitors from ASCO 2021.
Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer
Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Released: August 24, 2021
For further information concerning Lilly grant funding,
visit www.lillygrantoffice.com.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.